Total and free mycophenolic acid and its 7-O-glucuronide metabolite in Chinese adult renal transplant patients: Pharmacokinetics and application of limited sampling strategies

European Journal of Clinical Pharmacology

Volumn 63, Issue 1, 2007, Pages 27-37

  Jiao, Zheng ^a,b   Zhong, Jian Yong ^b   Zhang, Ming ^b   Shi, Xiao Jin ^b   Yu, Yun Qiu ^a   Lu, Wei Yue ^a  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Limited sampling strategy; Mycophenolic acid; Mycophenolic acid 7 O glucuronide; Pharmacokinetics

Indexed keywords

ACETYLSALICYLIC ACID; ACICLOVIR; ALPRAZOLAM; BENAZEPRIL; CALCINEURIN INHIBITOR; CARBAMAZEPINE; CORTICOSTEROID; CYCLOSPORIN A; DRUG METABOLITE; GANCICLOVIR; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYCOPHENOLIC ACID 7 O GLUCURONIDE; PREDNISOLONE; PREDNISONE; RAPAMYCIN; TACROLIMUS; UNCLASSIFIED DRUG; VALACICLOVIR;

ACUTE GRAFT REJECTION; ADULT; AREA UNDER THE CURVE; ARTICLE; CAUCASIAN; CLINICAL ARTICLE; COHORT ANALYSIS; CONCENTRATION RESPONSE; DRUG SUBSTITUTION; FEMALE; GRAFT RECIPIENT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LIVER DYSFUNCTION; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SAMPLING; UNSPECIFIED SIDE EFFECT;

ADULT; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD PROTEINS; CHINA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; GLUCURONIDES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PRODRUGS; PROTEIN BINDING;

EID: 33845875993     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-006-0215-y     Document Type: Article

References (56)

1. European Mycophenolate Mofetil Cooperative Study Group (1995) Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 345:1321-1325
2. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group (1996) A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 61:1029-1037
3. Odorico JS, Pirsch JD, Knechtle SJ, D'Alessandro AM, Sollinger HW (1998) A study comparing mycophenolate mofetil to azathioprine in simultaneous pancreas-kidney transplantation. Transplantation 66:1751-1759
4. Shaw LM, Korecka M, Venkataramanan R, Goldberg L, Bloom R, Brayman KL (2003) Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant 3:534-542
5. Sollinger HW (1995) Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 60:225-232
6. Wiesner R, Rabkin J, Klintmalm G, McDiarmid S, Langnas A, Punch J, McMaster P, Kalayoglu M, Levy G, Freeman R, Bismuth H, Neuhaus P, Mamelok R, Wang W (2001) A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 7:442-450
7. Allison A, Eugu E (1993) The design and development of an immunosuppressive drug, mycophenolate mofetil. Springer Semin Immunopathol 14:353-380
8. Nowak I, Shaw LM (1995) Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem 41:1011-1017
9. Bullingham RE, Nicholls AJ, Kamm BR (1998) Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 34:429-455
10. Shipkova M, Schutz E, Armstrong VW, Niedmann PD, Wieland E, Oellerich M (1999) Overestimation of mycophenolic acid by EMIT correlates with MPA metabolite. Transplant Proc 31:1135-1137
11. Atcheson BA, Taylor PJ, Kirkpatrick CM, Duffull SB, Mudge DW, Pillans PI, Johnson DW, Tett SE (2004) Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminemia. Ther Drug Monit 26:284-286
12. Cho EK, Han DJ, Kim SC, Burckart GJ, Venkataramanan R, Oh JM (2004) Pharmacokinetic study of mycophenolic acid in Korean kidney transplant patients. J Clin Pharmacol 44:743-750
13. Cremers S, Schoemaker R, Scholten E, den Hartigh J, Konig-Quartel J, van Kan E, Paul L, de Fijter J (2005) Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling. Br J Clin Pharmacol 60:249-256
14. Filler G, Zimmering M, Mai I (2000) Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression. Pediatr Nephrol 14:100-104
15. Kaplan B, Meier-Kriesche HU, Friedman G, Mulgaonkar S, Gruber S, Korecka M, Brayman KL, Shaw LM (1999) The effect of renal insufficiency on mycophenolic acid protein binding. J Clin Pharmacol 39:715-720
16. Kuypers DR, Claes K, Evenepoel P, Maes B, Coosemans W, Pirenne J, Vanrenterghem Y (2003) Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients. J Clin Pharmacol 43:866-880
17. Naderer OJ, Dupuis RE, Heinzen EL, Wiwattanawongsa K, Johnson MW, Smith PC (2005) The influence of norfloxacin and metronidazole on the disposition of mycophenolate mofetil. J Clin Pharmacol 45:219-226
18. Pou L, Brunet M, Cantarell C, Vidal E, Oppenheimer F, Monforte V, Vilardell J, Roman A, Martorell J, Capdevila L (2001) Mycophenolic acid plasma concentrations: influence of comedication. Ther Drug Monit 23:35-38
19. Shaw LM, Korecka M, Aradhye S, Grossman R, Barker C, Naji A, Brayman KL (1998) Scientific principles for mycophenolic acid therapeutic drug monitoring. Transplant Proc 30:2234-2236
20. Shaw LM, Korecka M, Aradhye S, Grossman R, Bayer L, Innes C, Cucciara A, Barker C, Naji A, Nicholls A, Brayman K (2000) Mycophenolic acid area under the curve values in African American and Caucasian renal transplant patients are comparable. J Clin Pharmacol 40:624-633
21. Shipkova M, Armstrong VW, Kuypers D, Perner F, Fabrizi V, Holzer H, Wieland E, Oellerich M (2001) Effect of cyclosporine withdrawal on mycophenolic acid pharmacokinetics in kidney transplant recipients with deteriorating renal function: preliminary report. Ther Drug Monit 23:717-721
22. van Gelder T, Klupp J, Barten MJ, Christians U, Morris RE (2001) Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 23:119-128
23. Shaw LM, Mick R, Nowak I, Korecka M, Brayman KL (1998) Pharmacokinetics of mycophenolic acid in renal transplant patients with delayed graft function. J Clin Pharmacol 38:268-275
24. Kuypers DR, Naesens M, Vermeire S, Vanrenterghem Y (2005) The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid doseinterval exposure in de novo renal allograft recipients. Clin Pharmacol Ther 78:351-361
25. Kuypers DR, Claes K, Evenepoel P, Maes B, Vanrenterghem Y (2004) Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients. Clin Pharmacol Ther 75:434-447
26. Liang MZ, Lu YP, Nan F, Yu Q, Qin YP, Zou YG (2004) Pharmacokinetics of mycophenolic acid after a single and multiple oral doses of mycophenolate mofetil in Chinese renal transplant recipients. Transplant Proc 36:2065-2067
27. Lu XY, Huang HF, Sheng-Tu JZ, Liu J (2005) Pharmacokinetics of mycophenolic acid in Chinese kidney transplant patients. J Zhejiang Univ Sci B 6:885-891
28. Mourad M, Malaise J, Chaib Eddour D, De Meyer M, Konig J, Schepers R, Squifflet JP, Wallemacq P (2001) Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. Clin Chem 47:88-94
29. Oellerich M, Shipkova M, Schutz E, Wieland E, Weber L, Tonshoff B, Armstrong VW (2000) Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. Ther Drug Monit 22:20-26
30. Pescovitz MD, Conti D, Dunn J, Gonwa T, Halloran P, Sollinger H, Tomlanovich S, Weinstein S, Inokuchi S, Kiberd B, Kittur D, Merion RM, Norman D, Shoker A, Wilburn R, Nicholls AJ, Arterburn S, Dumont E (2000) Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics. Clin Transplant 14:179-188
31. van Hest RM, Mathot RA, Vulto AG, Le Meur Y, van Gelder T (2004) Mycophenolic acid in diabetic renal transplant recipients: pharmacokinetics and application of a limited sampling strategy. Ther Drug Monit 26:620-625
32. Weber LT, Lamersdorf T, Shipkova M, Niedmann PD, Wiesel M, Zimmerhackl LB, Staskewitz A, Schutz E, Mehls O, Oellerich M, Armstrong VW, Tonshoff B (1999) Area under the plasma concentration-time curve for total, but not for free, mycophenolic acid increases in the stable phase after renal transplantation: a longitudinal study in pediatric patients. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. Ther Drug Monit 21:498-506
33. Weber LT, Shipkova M, Armstrong VW, Wagner N, Schutz E, Mehls O, Zimmerhackl LB, Oellerich M, Tonshoff B (2002) The pharmacokinetic- pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German Study Group on Mycophenolate Mofetil Therapy. J Am Soc Nephrol 13:759-768
34. Atcheson BA, Taylor PJ, Mudge DW, Johnson DW, Hawley CM, Campbell SB, Isbel NM, Pillans PI, Tett SE (2005) Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant. Br J Clin Pharmacol 59:271-280
35. Johnson AG, Rigby RJ, Taylor PJ, Jones CE, Allen J, Franzen K, Falk MC, Nicol D (1999) The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant recipients. Clin Pharmacol Ther 66:492-500
36. Jirasiritham S, Sumethkul V, Mavichak V, Na-Bangchang K (2004) The pharmacokinetics of mycophenolate mofetil in Thai kidney transplant recipients. Transplant Proc 36:2076-2078
37. Tsang WK, Tong KL, Yeung S, Lee W, Chan HW (2000) Efficacy and safety of mycophenolate mofetil in different dosages in Asian renal allograft recipients. Transplant Proc 32:1755-1756
38. Wang X, Tang X, Xu D (1998) Immunosuppressive effect of mycophenolate mofetil with two different dosages in cadaveric renal transplantation: a short study. Transplant Proc 30:3573-3574
39. Suhail SM, Vathsala A, Lou HX, Woo KT (2000) Safety and efficacy of mycophenolate mofetil for prophylaxis in Asian renal transplant recipients. Transplant Proc 32:1757-1758
40. van Gelder T, Hilbrands LB, Vanrenterghem Y, Weimar W, de Fijter JW, Squifflet JP, Hene RJ, Verpooten GA, Navarro MT, Hale MD, Nicholls AJ (1999) A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 68:261-266
41. Shaw LM, Holt DW, Oellerich M, Meiser B, van Gelder T (2001) Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit 23:305-315
42. van Gelder T, Meur YL, Shaw LM, Oellerich M, DeNofrio D, Holt C, Holt DW, Kaplan B, Kuypers D, Meiser B, Toenshoff B, Mamelok RD (2006) Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 28:145-154
43. Jiao Z, Zhong Y, Shen J, Yu YQ (2005) Simple high-performance liquid chromatographic assay, with post-column derivatization, for simultaneous determination of mycophenolic acid and its glucuronide metabolite in human plasma and urine. Chromatographia 62:363-371
44. Efron B, Gong G (1983) A leisurely look at the bootstrap, the jackknife, and cross-validation. Amer Stat 37:36-48
45. Miller R (1974) The jackknife - a review. Biometrika 61:1-15
46. Sheiner LB, Beal SL (1981) Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9:503-512
47. Bland JM, Altman DG (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1:307-310
48. Mandla R, Line PD, Midtvedt K, Bergan S (2003) Automated determination of free mycophenolic acid and its glucuronide in plasma from renal allograft recipients. Ther Drug Monit 25:407-414
49. Johnson JA (1997) Influence of race or ethnicity on pharmacokinetics of drugs. J Pharm Sci 86:1328-1333
50. Yeung S, Tong KL, Tsang WK, Tang HL, Fung KS, Chan HW, Chan AY, Chan L (2001) Determination of mycophenolate area under the curve by limited sampling strategy. Transplant Proc 33:1052-1053
51. Schutz E, Armstrong VW, Shipkova M, Weber L, Niedmann PD, Lammersdorf T, Wiesel M, Mandelbaum A, Zimmerhackl LB, Mehls O, Tonshoff B, Oellerich M (1998) Limited sampling strategy for the determination of mycophenolic acid area under the curve in pediatric kidney recipients. German Study Group on MMF Therapy in Pediatric Renal Transplant Recipients. Transplant Proc 30:1182-1184
52. Filler G, Mai I (2000) Limited sampling strategy for mycophenolic acid area under the curve. Ther Drug Monit 22:169-173
53. Le Guellec C, Buchler M, Giraudeau B, Le Meur Y, Gakoue JE, Lebranchu Y, Marquet P, Paintaud G (2002) Simultaneous estimation of cyclosporin and mycophenolic acid areas under the curve in stable renal transplant patients using a limited sampling strategy. Eur J Clin Pharmacol 57:805-811
54. Pawinski T, Hale M, Korecka M, Fitzsimmons WE, Shaw LM (2002) Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus. Clin Chem 48:1497-1504
55. Weber LT, Schutz E, Lamersdorf T, Shipkova M, Niedmann PD, Oellerich M, Zimmerhackl LB, Staskewitz A, Mehls O, Armstrong VW, Tonshoff B (1999) Therapeutic drug monitoring of total and free mycophenolic acid (MPA) and limited sampling strategy for determination of MPA-AUC in paediatric renal transplant recipients. The German Study Group on Mycophenolate Mofetil (MMF) Therapy. Nephrol Dial Transplant 14 Suppl 4:34-35
56. Willis C, Taylor PJ, Salm P, Tett SE, Pillans PI (2000) Evaluation of limited sampling strategies for estimation of 12-hour mycophenolic acid area under the plasma concentration-time curve in adult renal transplant patients. Ther Drug Monit 22:549-554